Corcept Therapeutics Incorporated (NASDAQ: CORT) stock closed at 22.76 per share at the end of the most recent trading day (a -0.78% change compared to the prior day closing price) with a volume of 412.99K shares and market capitalization of 2.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 236 people. Corcept Therapeutics Incorporated CEO is Joseph K. Belanoff.

The one-year performance of Corcept Therapeutics Incorporated stock is 89.08%, while year-to-date (YTD) performance is -13%. CORT stock has a five-year performance of 364.49%. Its 52-week range is between 11.91 and 31.18, which gives CORT stock a 52-week price range ratio of 56.31%

Corcept Therapeutics Incorporated currently has a PE ratio of 27.00, a price-to-book (PB) ratio of 5.14, a price-to-sale (PS) ratio of 10.10, a price to cashflow ratio of 18.70, a PEG ratio of 2.32, a ROA of 20.77%, a ROC of 25.52% and a ROE of 22.86%. The company’s profit margin is 29.01%, its EBITDA margin is 37.90%, and its revenue ttm is $260.63 Million , which makes it $2.22 revenue per share.

Of the last four earnings reports from Corcept Therapeutics Incorporated, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.21 for the next earnings report. Corcept Therapeutics Incorporated’s next earnings report date is 03rd May 2021.

The consensus rating of Wall Street analysts for Corcept Therapeutics Incorporated is Moderate Buy (2.17), with a target price of $27, which is +18.63% compared to the current price. The earnings rating for Corcept Therapeutics Incorporated stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Corcept Therapeutics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Corcept Therapeutics Incorporated has a Sell technical analysis rating based on Technical Indicators (ADX : 18.16, ATR14 : 1.02, CCI20 : -87.28, Chaikin Money Flow : -0.13, MACD : -1.29, Money Flow Index : 35.73, ROC : -3.11, RSI : 40.99, STOCH (14,3) : 25.60, STOCH RSI : 0.90, UO : 41.35, Williams %R : -74.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Corcept Therapeutics Incorporated in the last 12-months were: Daniel N. Swisher (Option Excercise at a value of $196 500), Daniel N. Swisher (Sold 30 000 shares of value $557 810 ), David L. Mahoney (Option Excercise at a value of $270 549), G. Charles Robb (Option Excercise at a value of $1 220 000), G. Charles Robb (Sold 115 500 shares of value $3 265 148 ), George Leonard Baker (Buy at a value of $1 443 984), George Leonard Baker (Option Excercise at a value of $208 200), George Leonard Baker (Sold 60 000 shares of value $942 120 ), Hazel Hunt (Option Excercise at a value of $198 000), Joseph Douglas Lyon (Option Excercise at a value of $697 250), Joseph Douglas Lyon (Sold 75 000 shares of value $1 956 920 ), Joseph K. Belanoff (Option Excercise at a value of $3 536 000), Sean Maduck (Option Excercise at a value of $40 760), Sean Maduck (Sold 12 389 shares of value $355 152 )